Abivax(US:ABVX) Yahoo Finance·2026-01-02 08:28Group 1 - ABIVAX Societe Anonyme (NASDAQ:ABVX) experienced a remarkable increase of 1,742.28 percent in 2025, driven by positive analyst outlooks, strong clinical trial results, and its inclusion in the Nasdaq biotechnology index [1][2] - The company officially joined the Nasdaq biotechnology index on December 22, which tracks the performance of biotechnology and pharmaceutical companies listed on Nasdaq, marking a significant milestone for ABIVAX [2] - ABIVAX's Chief Finance Officer, Didier Blondel, highlighted the progress made in advancing obefazimod through successful Phase 3 ABTECT Induction trials for ulcerative colitis, enhancing the company's visibility in the global biotechnology community [2] Group 2 - ABIVAX received "buy" recommendations from investment firms such as Guggenheim Securities, Truist Financial, and Citizens, with price targets set at $175, $140, and $131 respectively, reflecting a positive outlook from analysts [2] - The Phase 3 trial results for obefazimod indicated significant improvements in patients with moderate to severe ulcerative colitis, suggesting real disease healing [2]